Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows

Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows
Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients' response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the European Society for Medical Oncology (ESMO) Congress 2019, being held Sept. 27 to Oct. 1 in Barcelona, Spain. Jonathan Ledermann, professor at the University College of London (UCL) Cancer Institute, will present the trial’s findings in a poster titled, "Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the Phase 3 study ARIEL3 of rucaparib maintenance treatment." Rubraca is a PARP inhibitor that works by blocking the activity of PARP enzymes. These enzymes are involved in DNA repair, and in the control of programmed cell death. By blocking the activity of these enzymes, Rubraca prevents cancer cells from repairing their DNA, eventually eliminating them. The
Subscribe or to access all post and page content.